

Agostino Cortelezzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2051913/publications.pdf>

Version: 2024-02-01

182
papers

5,961
citations

87843

38
h-index

95218

68
g-index

182
all docs

182
docs citations

182
times ranked

8068
citing authors

#	ARTICLE	IF	CITATIONS
1	Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. <i>Leukemia</i> , 2020, 34, 441-450.	3.3	8
2	Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18–65 years: NILG ALL 10/07. <i>Blood Cancer Journal</i> , 2020, 10, 119.	2.8	29
3	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	1.7	64
4	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , 2019, 11, 896.	1.7	16
5	Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: Results from a single-centre study. <i>PLoS ONE</i> , 2019, 14, e0216715.	1.1	18
6	Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL). <i>Hematological Oncology</i> , 2019, 37, 505-507.	0.8	2
7	Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. <i>Haematologica</i> , 2019, 104, e222-e223.	1.7	42
8	Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. <i>Haematologica</i> , 2018, 103, e245-e248.	1.7	29
9	Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2018, 55, 202-208.	1.8	6
10	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	1.7	30
11	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , 2018, 32, 1869-1873.	3.3	8
12	Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2516-2517.	0.6	3
13	Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , 2018, 93, E88-E91.	2.0	18
14	Paroxysmal Nocturnal Hemoglobinuria (Pnh): Brain Mri Ischemic Lesions In Neurologically Asymptomatic Patients. <i>Scientific Reports</i> , 2018, 8, 476.	1.6	8
15	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 25.	2.8	26
16	Heterogeneity among splanchnic vein thrombosis associated with myeloproliferative neoplasms. <i>European Journal of Internal Medicine</i> , 2018, 52, e25-e26.	1.0	5
17	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , 2018, 97, 95-100.	0.8	32
18	An Unusual Coexistence of Primary Central Nervous System Non-Hodgkin's Lymphoma and Acute Promyelocytic Leukemia. <i>Case Reports in Hematology</i> , 2018, 2018, 1-5.	0.3	1

#	ARTICLE	IF	CITATIONS
19	Autoimmune hemolytic anemia, autoimmune neutropenia and aplastic anemia in the elderly. <i>European Journal of Internal Medicine</i> , 2018, 58, 77-83.	1.0	9
20	Use of Laser Assisted Optical Rotational Cell Analyzer (LoRRca MaxSis) in the Diagnosis of RBC Membrane Disorders, Enzyme Defects, and Congenital Dyserythropoietic Anemias: A Monocentric Study on 202 Patients. <i>Frontiers in Physiology</i> , 2018, 9, 451.	1.3	57
21	Prospective evaluation of metabolic syndrome and its features in a single-center series of hematopoietic stem cell transplantation recipients. <i>Annals of Hematology</i> , 2018, 97, 2471-2478.	0.8	5
22	Predictive value of the <sc>CLL</sc>â€<sc>IPI</sc> in <sc>CLL</sc> patients receiving chemo-immunotherapy as first-line treatment. <i>European Journal of Haematology</i> , 2018, 101, 703-706.	1.1	8
23	Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers. <i>American Journal of Hematology</i> , 2018, 93, E243-E246.	2.0	48
24	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , 2018, 93, E216-E219.	2.0	15
25	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. <i>Blood</i> , 2018, 132, 3118-3118.	0.6	6
26	P53 and CD34 Immunohistochemical Expression on Bone Marrow Biopsy As Predictive Marker of Response to Erythropoietin in Low Risk Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 5511-5511.	0.6	0
27	Oxidative status in treatment-naïve essential thrombocythemia: a pilot study in a single center. <i>Hematological Oncology</i> , 2017, 35, 335-340.	0.8	0
28	Early detection of pulmonary hypertension in primary myelofibrosis: The role of echocardiography, cardiopulmonary exercise testing, and biomarkers. <i>American Journal of Hematology</i> , 2017, 92, E47-E48.	2.0	5
29	Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. <i>British Journal of Haematology</i> , 2017, 177, 741-750.	1.2	23
30	Chronic lymphocytic leukemia and prognostic models: A bridge between clinical and biological markers. <i>American Journal of Hematology</i> , 2017, 92, E135-E137.	2.0	6
31	Multifactorial neutropenia in a patient with acute promyelocytic leukemia and associated large granular lymphocyte expansion: A case report. <i>Oncology Letters</i> , 2017, 13, 1307-1310.	0.8	6
32	Clinical evolution of autoimmune cytopenias to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and bone marrow failure syndromes. <i>American Journal of Hematology</i> , 2017, 92, E26-E29.	2.0	17
33	Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia. <i>Annals of Hematology</i> , 2017, 96, 1953-1954.	0.8	7
34	An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review. <i>Leukemia Research Reports</i> , 2017, 8, 7-10.	0.2	6
35	Clinical management of peripherally inserted central catheters compared to conventional central venous catheters in patients with hematological malignancies: A large multicenter study of the <sc>REL</sc> <sc>GROUP</sc> (Rete Ematologica Lombarda - Lombardy Hematologic Network,) <i>TJ ETQq1 I 0.784314 19gBT /Ove</i>	2.0	19
36	â€Gardos Channelopathyâ€™: a variant of hereditary Stomatocytosis with complex molecular regulation. <i>Scientific Reports</i> , 2017, 7, 1744.	1.6	68

#	ARTICLE	IF	CITATIONS
37	Biological and molecular characterization of a rare case of cutaneous Richter syndrome. <i>Hematological Oncology</i> , 2017, 35, 869-874.	0.8	4
38	Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications. <i>Stem Cells International</i> , 2017, 2017, 1-13.	1.2	15
39	The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 88021-88033.	0.8	14
40	Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera. <i>Medicine (United States)</i> , 2016, 95, e3697.	0.4	8
41	Detection of erythroblast antibodies in mitogen-stimulated bone marrow cultures from patients with myelodysplastic syndromes. <i>Transfusion</i> , 2016, 56, 2037-2041.	0.8	12
42	18F-Choline PET/CT-Positive Lytic Bone Lesions in Prostate Cancer and Accidental Myeloma Detection. <i>Clinical Nuclear Medicine</i> , 2016, 41, 394-396.	0.7	6
43	Anagrelide and Mutational Status in Essential Thrombocythemia. <i>BioDrugs</i> , 2016, 30, 219-223.	2.2	7
44	Unbiased pro-thrombotic features at diagnosis in 977 thrombocytopenic patients with Philadelphia-negative chronic myeloproliferative neoplasms. <i>Leukemia Research</i> , 2016, 46, 18-25.	0.4	13
45	Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1983-1987.	2.0	77
46	Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. <i>American Journal of Hematology</i> , 2016, 91, 692-699.	2.0	54
47	Compendium of <i>FAM46C</i> gene mutations in plasma cell dyscrasias. <i>British Journal of Haematology</i> , 2016, 174, 642-645.	1.2	34
48	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter Oâ€CLLâ€GISL study. <i>European Journal of Haematology</i> , 2016, 96, 36-45.	1.1	7
49	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) role in hematopoiesis and in hematologic diseases: A critical review. <i>Toxicology</i> , 2016, 374, 60-68.	2.0	21
50	Reply To: Assessment of Liver and Spleen Stiffness in Patients With Myelofibrosis Using FibroScan and Shear Wave Elastography. <i>Ultrasound Quarterly</i> , 2016, 32, 317-317.	0.3	0
51	Finding a new therapeutic approach for no-option Parkinsonisms: mesenchymal stromal cells for progressive supranuclear palsy. <i>Journal of Translational Medicine</i> , 2016, 14, 127.	1.8	41
52	Marked eosinophilia as initial presentation of breast implant-associated anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2712-2715.	0.6	20
53	A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes. <i>Nature Medicine</i> , 2016, 22, 727-734.	15.2	68
54	Reduced 25-OH vitamin D in patients with autoimmune cytopenias, clinical correlations and literature review. <i>Autoimmunity Reviews</i> , 2016, 15, 770-775.	2.5	30

#	ARTICLE	IF	CITATIONS
55	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016, 7, 80083-80090.	0.8	24
56	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	0.6	197
57	A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2015, 100, e501-e504.	1.7	22
58	Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 786-793.	1.7	27
59	Detection of red blood cell antibodies in mitogen-stimulated cultures from patients with hereditary spherocytosis. <i>Transfusion</i> , 2015, 55, 2930-2938.	0.8	14
60	Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias. <i>American Journal of Hematology</i> , 2015, 90, E149-51.	2.0	31
61	Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience. <i>American Journal of Hematology</i> , 2015, 90, 970-974.	2.0	2
62	Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?. <i>Oncotarget</i> , 2015, 6, 33944-33951.	0.8	59
63	Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. <i>Leukemia Research</i> , 2015, 39, 840-845.	0.4	12
64	Early lenalidomide treatment for low and intermediate International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence. <i>Cancer Medicine</i> , 2015, 4, 1789-1797.	1.3	18
65	PDGFB hypomethylation is a favourable prognostic biomarker in primary myelofibrosis. <i>Leukemia Research</i> , 2015, 39, 236-241.	0.4	10
66	Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib. <i>Annals of Hematology</i> , 2015, 94, 1749-1751.	0.8	7
67	Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. <i>Leukemia Research</i> , 2015, 39, 525-529.	0.4	17
68	Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis. <i>Annals of Hematology</i> , 2015, 94, 881-882.	0.8	16
69	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 3150-3158.	0.6	23
70	Is chronic neutropenia always a benign disease? Evidences from a 5-year prospective study. <i>European Journal of Internal Medicine</i> , 2015, 26, 611-615.	1.0	17
71	Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report. <i>Clinical Case Reports (discontinued)</i> , 2015, 3, 650-655.	0.2	13
72	Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single centre. <i>British Journal of Haematology</i> , 2015, 170, 890-892.	1.2	16

#	ARTICLE	IF	CITATIONS
73	Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. <i>Leukemia Research</i> , 2015, 39, 1066-1070.	0.4	29
74	Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study. <i>British Journal of Haematology</i> , 2015, 168, 455-459.	1.2	9
75	Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukaemia. <i>PLoS ONE</i> , 2015, 10, e0118801.	1.1	15
76	Long-Term Outcome of Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sézary Syndrome: A European Society for Blood and Marrow Transplantation Lymphoma Working Party Extended Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3347-3348.	0.8	85
77	Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms: An European leukemia network study. <i>American Journal of Hematology</i> , 2014, 89, E200-5.	2.0	42
78	Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression. <i>Leukemia and Lymphoma</i> , 2014, 55, 1768-1773.	0.6	20
79	Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients. <i>European Journal of Internal Medicine</i> , 2014, 25, 63-66.	1.0	24
80	Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. <i>Leukemia and Lymphoma</i> , 2014, 55, 841-847.	0.6	17
81	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2014, 89, 480-486.	2.0	104
82	Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study. <i>Journal of Translational Medicine</i> , 2014, 12, 14.	1.8	30
83	High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. <i>British Journal of Haematology</i> , 2014, 165, 629-639.	1.2	52
84	Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? <i>Leukemia and Lymphoma</i> , 2014, 55, 1261-1265.	0.6	14
85	Successful Treatment With Imatinib in a Patient With Chronic Eosinophilic Leukemia Not Otherwise Specified. <i>Journal of Clinical Oncology</i> , 2014, 32, e37-e39.	0.8	7
86	Autoimmune cytopenias in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2014, 89, 1055-1062.	2.0	93
87	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. <i>Leukemia Research</i> , 2014, 38, 198-203.	0.4	4
88	Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 612-621.	1.5	38
89	Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. <i>Blood</i> , 2014, 124, 2930-2936.	0.6	268
90	Imatinib and ruxolitinib association: first experience in two patients. <i>Haematologica</i> , 2014, 99, e76-e77.	1.7	26

#	ARTICLE	IF	CITATIONS
91	Identification of kitM541L somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. <i>Oncotarget</i> , 2014, 5, 4665-4670.	0.8	28
92	Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. <i>Annals of Hematology</i> , 2013, 92, 25-32.	0.8	23
93	Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. <i>European Journal of Haematology</i> , 2013, 91, 546-551.	1.1	50
94	Total body computed tomography scan in the initial workup of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter Oâ€CLL1â€GISL study. <i>American Journal of Hematology</i> , 2013, 88, 539-544.	2.0	10
95	Chromosome 2p gain in monoclonal Bâ€cell lymphocytosis and in early stage chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013, 88, 24-31.	2.0	27
96	Bâ€cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013, 88, 32-36.	2.0	36
97	Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome. <i>Cancer Cell</i> , 2013, 24, 90-104.	7.7	168
98	Increased prevalence of autoimmune phenomena in myelofibrosis: Relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns. <i>Leukemia Research</i> , 2013, 37, 1509-1515.	0.4	35
99	Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. <i>Leukemia and Lymphoma</i> , 2013, 54, 2458-2465.	0.6	29
100	Biosensors in Clinical Practice: Focus on Oncohematology. <i>Sensors</i> , 2013, 13, 6423-6447.	2.1	61
101	Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features. <i>Clinical Cancer Research</i> , 2013, 19, 5890-5900.	3.2	60
102	High Levels of Vascular Endothelial Growth Factor Protein Expression Are Associated With an Increased Risk of Transfusion Dependence in Myelodysplastic Syndromes. <i>American Journal of Clinical Pathology</i> , 2013, 139, 380-387.	0.4	10
103	Bone marrow localisation of metastatic melanoma and synchronous leukaemic evolution of low-risk myelodysplastic syndrome. <i>Journal of Clinical Pathology</i> , 2013, 66, 75-78.	1.0	4
104	Analytical performance and method comparison study of the total homocysteine immunoassay on the AIA 600II analyser. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, e273-5.	1.4	1
105	Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma. <i>Advances in Hematology</i> , 2013, 2013, 1-2.	0.6	1
106	Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. <i>Blood</i> , 2013, 121, 4521-4528.	0.6	81
107	Allogeneic Hematopoietic Cell Transplantation For Patients With Mycosis Fungoides and Sezary Syndrome: The Experience Of The EBMT Lymphoma Working Party With An Extended Five-Year Follow Up. <i>Blood</i> , 2013, 122, 2094-2094.	0.6	2
108	Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms. <i>Blood</i> , 2013, 122, 4068-4068.	0.6	10

#	ARTICLE	IF	CITATIONS
109	A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. <i>Blood</i> , 2013, 122, 4177-4177.	0.6	2
110	Clinical Heterogeneity Of Autoimmune Hemolytic Anemia: A 35-Years Retrospective Study Of 157 Patients. <i>Blood</i> , 2013, 122, 3428-3428.	0.6	0
111	A Randomized Open-Label Study To Evaluate The Efficacy Of Azacitidine For Post-Remission Therapy Of Acute Myeloid Leukemia In Elderly Patients (QOLESS AZA-AMLE). <i>Blood</i> , 2013, 122, 3967-3967.	0.6	0
112	The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. <i>Modern Pathology</i> , 2012, 25, 1193-1202.	2.9	99
113	Diagnostic power of laboratory tests for hereditary spherocytosis: a comparison study in 150 patients grouped according to molecular and clinical characteristics. <i>Haematologica</i> , 2012, 97, 516-523.	1.7	165
114	An acquired factor VIII inhibitor in a myeloproliferative neoplasm presenting with severe retroperitoneal hemorrhage. <i>Leukemia and Lymphoma</i> , 2012, 53, 2296-2298.	0.6	2
115	Successful management with intravenous immunoglobulins in alemtuzumab-induced acute inflammatory demyelinating neuropathy: clinical report of three patients. <i>Immunopharmacology and Immunotoxicology</i> , 2012, 34, 717-720.	1.1	7
116	Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice. <i>Immunopharmacology and Immunotoxicology</i> , 2012, 34, 740-753.	1.1	16
117	Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia. <i>Advances in Hematology</i> , 2012, 2012, 1-7.	0.6	8
118	CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. <i>Haematologica</i> , 2012, 97, 568-571.	1.7	25
119	Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. <i>Blood</i> , 2012, 119, 3691-3697.	0.6	118
120	Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. <i>Blood</i> , 2012, 120, 858-867.	0.6	94
121	A new variant of phosphoglycerate kinase deficiency (p.I371K) with multiple tissue involvement: Molecular and functional characterization. <i>Molecular Genetics and Metabolism</i> , 2012, 106, 455-461.	0.5	30
122	Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 424-429.	0.6	11
123	Metabolic syndrome in patients with hematological diseases. <i>Expert Review of Hematology</i> , 2012, 5, 439-458.	1.0	15
124	Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 936-937.	2.0	14
125	Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors. <i>Clinical Cancer Research</i> , 2012, 18, 1870-1878.	3.2	33
126	An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2012, 156, 481-489.	1.2	17

#	ARTICLE	IF	CITATIONS
127	Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma. <i>Annals of Hematology</i> , 2012, 91, 73-82.	0.8	36
128	B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1780-1780.	0.6	0
129	Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes. <i>PLoS ONE</i> , 2011, 6, e23109.	1.1	95
130	Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2011, 6, e24313.	1.1	36
131	Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group. <i>Haematologica</i> , 2011, 96, 277-283.	1.7	47
132	Circulating and progenitor endothelial cells are abnormal in patients with different types of von Willebrand disease and correlate with markers of angiogenesis. <i>American Journal of Hematology</i> , 2011, 86, 650-656.	2.0	20
133	The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: A retrospective multicentric GIMEMA experience. <i>American Journal of Hematology</i> , 2011, 86, 1007-1012.	2.0	47
134	Prognostic Significance of Telomere Length in Chronic Lymphocytic Leukemia Patients in Early Stage Disease. <i>Blood</i> , 2011, 118, 3890-3890.	0.6	7
135	Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-Cell Receptors. <i>Blood</i> , 2011, 118, 2847-2847.	0.6	0
136	Thromboembolic Complications in Malignant Haematological Disorders. <i>Current Vascular Pharmacology</i> , 2010, 8, 482-494.	0.8	36
137	Oxidative stress is increased in primary and post-polycythemia vera myelofibrosis. <i>Experimental Hematology</i> , 2010, 38, 1058-1065.	0.2	39
138	The clinical and biological features of a series of immunophenotypic variant of B-CLL. <i>European Journal of Haematology</i> , 2010, 85, 120-129.	1.1	13
139	Changes in <i>RPS14</i> expression levels during lenalidomide treatment in Low- and Intermediate-risk myelodysplastic syndromes with chromosome 5q deletion. <i>European Journal of Haematology</i> , 2010, 85, 231-235.	1.1	25
140	Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. <i>Leukemia Research</i> , 2010, 34, e217-e218.	0.4	3
141	<i>RAS</i> Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant. <i>Clinical Cancer Research</i> , 2010, 16, 2246-2256.	3.2	123
142	The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. <i>Haematologica</i> , 2010, 95, 464-469.	1.7	37
143	Hepcidin Levels and Their Determinants In Different Types of Myelodysplastic Syndromes. <i>Blood</i> , 2010, 116, 4250-4250.	0.6	0
144	New SMAC-Mimetic Compounds Strongly Induce In Vitro Apoptosis of Human Lymphocytes From Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 1835-1835.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2009, 15, 5002-5007.	3.2	103
146	Systolic blood pressure peak during maximal exercise testing: A possible determinant of endothelial turnover in healthy subjects. <i>American Journal of Hematology</i> , 2009, 84, 449-450.	2.0	1
147	Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). <i>Blood</i> , 2009, 113, 4153-4162.	0.6	387
148	Gene Expression Changes in Bone Marrow of MDS Patients with Del(5q) During Lenalidomide Treatment.. <i>Blood</i> , 2009, 114, 2622-2622.	0.6	0
149	Lenalidomide for the Treatment of Low- and Int-1-Risk MDS with Del(5q): Efficacy and Quality of Life Study.. <i>Blood</i> , 2009, 114, 2763-2763.	0.6	1
150	Bone marrow glycophorinâ€positive erythroid cells of myelodysplastic patients responding to highâ€dose rHuEPO therapy have a different gene expression pattern from those of nonresponders. <i>American Journal of Hematology</i> , 2008, 83, 531-539.	2.0	11
151	Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. <i>Journal of Rheumatology</i> , 2008, 35, 1323-8.	1.0	38
152	Effects of simulated altitude (normobaric hypoxia) on cardiorespiratory parameters and circulating endothelial precursors in healthy subjects. <i>Respiratory Research</i> , 2007, 8, 58.	1.4	10
153	Survivin expression in â€low-riskâ€and â€high-riskâ€myelodysplastic syndromes. <i>Annals of Hematology</i> , 2007, 86, 185-189.	0.8	18
154	ZAP-70 immunoreactivity is a prognostic marker of disease progression in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 245-251.	0.6	16
155	Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. <i>Journal of Clinical Virology</i> , 2006, 35, 467-469.	1.6	38
156	Bone marrow endothelial progenitors are defective in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2006, 54, 2605-2615.	6.7	161
157	Endothelial Colony Forming Capacity is Related to C-Reactive Protein Levels in Healthy Subjects. <i>Current Neurovascular Research</i> , 2006, 3, 99-106.	0.4	23
158	Pathogenetic Role of Mature and Progenitor Endothelial Cells in Pre-Eclampsia.. <i>Blood</i> , 2006, 108, 3946-3946.	0.6	0
159	Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. <i>Haematologica</i> , 2006, 91, 1689-92.	1.7	61
160	Increased levels of circulating endothelial cells in chronic periaortitis as a marker of active disease. <i>Kidney International</i> , 2005, 68, 562-568.	2.6	24
161	Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. <i>British Journal of Haematology</i> , 2005, 129, 811-817.	1.2	134
162	A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2005, 46, 553-560.	0.6	21

#	ARTICLE	IF	CITATIONS
163	Stem Cells Defects in Systemic Sclerosis.. Blood, 2005, 106, 4194-4194.	0.6	0
164	A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia. Haematologica, 2005, 90, 410-2.	1.7	21
165	Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products. British Journal of Haematology, 2004, 125, 83-89.	1.2	31
166	Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis and Rheumatism, 2004, 50, 1296-1304.	6.7	146
167	Hematopoietic Stem Cell Transplantation in Adult Acute Lymphoblastic Leukemia: a Single-Centre Analysis. Leukemia and Lymphoma, 2004, 45, 1175-1180.	0.6	2
168	In Vitro Colony Growth, RAS Genes Sequencing, and Expression of Bcl-2 and Bax Proteins in Chronic Myelomonocytic Leukemia.. Blood, 2004, 104, 2379-2379.	0.6	0
169	Possible association between reactive oxygen metabolites and karyotypic abnormalities in myelodysplastic syndromes. Haematologica, 2003, 88, 594-7.	1.7	8
170	Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. British Journal of Haematology, 2002, 117, 379-386.	1.2	123
171	Hyperhomocysteinemia in Myelodysplastic Syndromes: Specific Association with Autoimmunity and Cardiovascular Disease. Leukemia and Lymphoma, 2001, 41, 147-150.	0.6	9
172	Biological and molecular characterization of PNH-like lymphocytes emerging after Campath-1H therapy. British Journal of Haematology, 2001, 112, 969-971.	1.2	16
173	FISH characterization of t(8;12)(q12;p13) observed as the sole karyotypic anomaly in a myelodysplastic syndrome patient. Cancer Genetics and Cytogenetics, 2001, 130, 75-78.	1.0	1
174	Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups. The Hematology Journal, 2001, 2, 117-126.	2.0	30
175	Efficacy of N-acetylcysteine and all-trans retinoic acid in restoring in vitro effective hemopoiesis in myelodysplastic syndromes. Leukemia Research, 2000, 24, 129-137.	0.4	10
176	Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?. The Hematology Journal, 2000, 1, 153-158.	2.0	62
177	Low plasma stem cell factor levels correlate with in vitro leukemic growth in myelodysplastic syndromes. Leukemia Research, 1999, 23, 271-275.	0.4	9
178	Effects of recombinant human stem cell factor (rhâ€šSCF) on colony formation and longâ€š-term bone marrow cultures (LTBMC) in patients with myelodysplastic syndromes. European Journal of Haematology, 1994, 52, 53-60.	1.1	18
179	Interferon therapy during the plateau phase of multiple myeloma: An update of the Swedish study. European Journal of Cancer & Clinical Oncology, 1991, 27, S45-S48.	0.9	10
180	Incidence of jaw lesions in 193 patients with multiple myeloma. Oral Surgery, Oral Medicine, and Oral Pathology, 1988, 65, 533-537.	0.6	61

#	ARTICLE	IF	CITATIONS
181	Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 1041-1045.	0.9	17
182	Therapy with Interferons in Blood Diseases. <i>Acta Haematologica</i> , 1987, 78, 64-69.	0.7	1